Details for New Drug Application (NDA): 211939
✉ Email this page to a colleague
NDA 211939 describes BONSITY, which is a drug marketed by Alvogen and is included in one NDA. It is available from one supplier. Additional details are available on the BONSITY profile page.
The generic ingredient in BONSITY is teriparatide. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the teriparatide profile page.
The generic ingredient in BONSITY is teriparatide. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the teriparatide profile page.
Summary for 211939
| Tradename: | BONSITY |
| Applicant: | Alvogen |
| Ingredient: | teriparatide |
| Patents: | 0 |
Suppliers and Packaging for NDA: 211939
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BONSITY | teriparatide | SOLUTION;SUBCUTANEOUS | 211939 | NDA | Alvogen, Inc. | 47781-652 | 47781-652-89 | 1 SYRINGE in 1 CARTON (47781-652-89) / 2.48 mL in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 0.62MG/2.48ML (0.25MG/ML) | ||||
| Approval Date: | Oct 4, 2019 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
